CD274 and non-small cell lung carcinoma: For example, the results from the phase II/III KEYNOTE-010 study showed that compared with docetaxel, pembrolizumab prolonged overall survival (OS) in previously treated advanced NSCLC patients with positive PD-L1 expression determined by immunohistochemistry (IHC) on at least 1% of TCs5.